Please correct the following errors:
The Clinical Potential of Novel Poly ADP-Ribose Polymerase Inhibitors for Improved Management of Epithelial Ovarian Cancer
EDUCATION IS THE BEST MEDICINE ®
North International Ballrom
720 South Michigan Avenue
Chicago, Illinois, 60605
Tel.: +1 (312) 922 44001
Apply 100% FREE To The Ultimate Coaching Program Today!
Fill out the form below to apply for free today. Zero Obligation.
Apply 100% FREE To The Ultimate Coaching Program Today!
Fill out the form below to apply for free today. Zero Obligation.
100% Privacy Guaranteed
IMPROVED MANAGEMENT OF EPITHELIAL OVARIAN CANCER
Date & Location
May 30, 2015
7:00pm
Hilton Chicago
North International Ballroom
720 South Michigan Avenue
Chicago, Illinois, 60605
Symposium Chair
Bradley J. Monk, MD, FACOG, FACS
Phoenix, Arizona
Subscribe
This is an independent, accredited educational activity held adjunct to the ASCO Annual Meeting. This presentation is not sponsored or endorsed by ASCO.
REGISTRATION
CHAIR
FACULTY
Ursula A Matulonis, MD
Dana-Farber Cancer Institute
AGENDA
| 7:00 pm | Registration and Buffet Dinner |
| 7:30 pm |
Welcome and Introductions Bradley J. Monk, MD, FACOG, FACS |
| 7:35 pm | Pre-Session Survey |
| 7:40 pm |
Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP Inhibitors Bradley J. Monk, MD, FACOGS, FACS |
| 7:50 pm |
Discussion and Q&A Bradley J. Monk, MD, FACOG, FACS |
| 7:55 pm |
Clinical Date with PARP Inhibitors in Ovarian Cancer Thomas J. Herzog, MD |
| 8:10 pm |
Challenging Clinical Cases: Novel PARP Inhibitors in the Clinic Maintenance Therapy: Bradley J Monk, MD, FACOG, FACS Disease Recurrence: Ursula A. Matulonis, MD Gastrointestinal Toxicity: Thomas J. Herzog, MD |
| 8:40 pm |
Ongoing Clinical Trials with PARP Inhibitors in Ovarian Cancer Ursula A. Matulonis, MD |
| 8:55 pm |
Panel Discussion: How to Integrate PARP Inhibitors into Current Treatment Paradigms? Bradley J. Monk, MD, FACOG, FACS; Thomas J. Herzog, MD; Ursula A. Matulonis, MD |
| 9:10 pm | Post-session Survey |
| 9:15 pm |
Summary of Key Points Bradley J. Monk, MD, FACOG, FACS |
| 9:20 pm | Adjourn |
CONTINUING MEDICAL EDUCATION
Imedex®, LLC is accredited by the Continuing Education Council for Continuing Medical Education to provide continuing medical education for physicians. Imedex®, LLC designates this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
WHO SHOULD ATTEND
These educational activities are designed to meet the educational needs of medical oncologists, gynecologic oncologists, oncology nurses, nurse practitioners, gynecologists, pathologists, pharmacists, researchers, and other healthcare professionals interested and/or involved in the care and treatment of patients with gynecologic cancers.
OBJECTIVES
Upon completion of this educational activity, participants should be better able to:
• Demonstrate enhanced understanding of BRCA-mutant tumors, PARP function in DNA repair, and the rationale for targeting the PARP pathway in the treatment of ovarian cancer
• Evaluate the benefits and risks of emerging PARP inhibitors in the treatment of BRCA-deficient ovarian cancer
• Recommend clinical trials of novel PARP inhibitors appropriately to ovarian cancer patients with unmet need
• Identify ways to overcome the challenges in incorporating PARP inhibitors into routine practice for ovarian cancer
SYMPOSIUM LOCATION
North International Ballrom
720 South Michigan Avenue
Chicago, Illinois, 60605
Tel.: +1 (312) 922 44001
iPAD INTERACTIVE TECHNOLOGY
Imedex will incorporate iPad technology into this activity. Each participant will have access to an iPad that contains real-time presentation content, speaker biographies, and educational objectives. Throughout the activity, learners can use their device to answer pre/post-activity questions, vote on case discussions, and submit questions to the faculty.
SUPPORT
The following company has provided an educational grant in support of this conference:
AstraZeneca
ORGANIZER
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Twitter: twitter.com/ImedexCME
Facebook: facebook.com/Imedex
Web: www.imedex.com
COPYRIGHT 2015 IMEDEX ©
IMPROVED MANAGEMENT OF EPITHELIAL OVARIAN CANCER
May 30th, 2015
6:30pm
Hilton Chicago
Chicago, Illinois, USA
This is an independent, accredited educational activity held adjunct to the ASCO Annual Meeting. This presentation is not sponsored or endorsed by ASCO.
Date & Location
May 30th, 2015
7:00pm
Hilton Chicago
North International Ballroom
720 South Michigan Avenue
Chicago, Illinois, USA
Symposium Chair
Bradley J. Monk, MD
University of Arizona Cancer Center-Phoenix
Creighton University School of Medicine at Dignity Health St. Joseph’s Hospital and Medical Center
Phoenix, Arizona
Subscribe
Enter your email address below and receive the lastest updates in oncology and/or gastroenterology in your inbox. Once you subscribe, you can refine your preferences to receive only the emails that interest you.
| 7:00 pm | Registration and Buffet Dinner |
| 7:30 pm |
Welcome and Introductions Bradley J. Monk, MD, FACOG, FACS |
| 7:35 pm | Pre-Session Survey |
| 7:40 pm |
Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP Inhibitors Bradley J. Monk, MD, FACOGS, FACS |
| 7:50 pm |
Discussion and Q&A Bradley J. Monk, MD, FACOG, FACS |
| 7:55 pm |
Clinical Date with PARP Inhibitors in Ovarian Cancer Thomas J. Herzog, MD |
| 8:10 pm |
Challenging Clinical Cases: Novel PARP Inhibitors in the Clinic Maintenance Therapy: Bradley J Monk, MD, FACOG, FACS Disease Recurrence: Ursula A. Matulonis, MD Gastrointestinal Toxicity: Thomas J. Herzog, MD |
| 8:40 pm |
Ongoing Clinical Trials with PARP Inhibitors in Ovarian Cancer Ursula A. Matulonis, MD |
| 8:55 pm |
Panel Discussion: How to Integrate PARP Inhibitors into Current Treatment Paradigms? Bradley J. Monk, MD, FACOG, FACS; Thomas J. Herzog, MD; Ursula A. Matulonis, MD |
| 9:10 pm | Post-session Survey |
| 9:15 pm |
Summary of Key Points Bradley J. Monk, MD, FACOG, FACS |
| 9:20 pm | Adjourn |